TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24281911
Drug: Flavor-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor-matched placebo administered 30 minutes before exercise (P30)
Study: 24281911
Drug: Flavor-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor-matched placebo administered 120 minutes before exercise (P120)
Study: 24281911
Drug: 2% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carbohydrate solution ingested 30 minutes before exercise
Study: 24281911
Drug: 0% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% carbohydrate solution ingested 30 minutes before exercise
Study: 24281911
Drug: 12% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% carbohydrate solution ingested 30 minutes before exercise
Study: 15839797
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cortisol
Study: 12887481
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg S. repens extract
Study: 10485422
Drug: Heparin-bonded (Carmeda)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded (Carmeda) circuits
Study: 1938849
Drug: Verapamil 40
Normalized name: verapamil 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 40 mg
Study: 3044425
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg
Study: 31923193
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 ?g every four hours as needed)
Study: 31923193
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vaginal misoprostol (25 to 50 ?g every six hours as needed)
Study: 31923193
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone (one to two mg every six hours as needed)
Study: 15777441
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vaginal misoprostol
Study: 31085679
Drug: Nicotinamide (NAM)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (NAM) 750 mg twice daily plus Lanthanum Carbonate (LC) 1000 mg thrice daily
Study: 29281192
Drug: Dried salted
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried salted plum consumption during HBO₂ therapy
Study: 26350942
Drug: Alternating arm
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating arm motion 30 Hz low amplitude WBV (Alt_30 Hz-L)
Study: 26350942
Drug: Double arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double arm motion 30Hz low amplitude WBV (Double_30Hz-L)
Study: 25398689
Drug: Abediterol 0.313
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 0.313 μg
Study: 27439370
Drug: Abediterol 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 0.625 μg
Study: 25398689
Drug: Abediterol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 1.25 μg
Study: 27439370
Drug: Abediterol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 2.5 μg
Study: 25398689
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of Abediterol
Study: 22260858
Drug: Doenjang (9.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doenjang (9.9 g/d for 12 weeks)
Study: 17927645
Drug: Telephone-administered behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered behavioral migraine management program (TAT)
Study: 17927645
Drug: Standard Triptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Triptan Treatment (TT)
Study: 15375787
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d Wheat germ policosanol (WGP) for 4 weeks
Study: 9733054
Drug: rhIL-2, 9000000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-2, 9000000 IU subcutaneously twice daily for 3 days before surgery
Study: 9733054
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rhIL-2 administration)
Study: 7984740
Drug: In-home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-home therapy program (6 weeks)
Study: 7984740
Drug: Traditional county
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional county services (no in-home therapy)
Study: 2725163
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment (antimicrobial chemotherapeutic agents)
Study: 2725163
Drug: Ototopical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ototopical treatment (nonallergenic disinfectants)
Study: 2725163
Drug: Azactam (systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azactam (systemic treatment)
Study: 2725163
Drug: Sulfamethoxazole plus
Normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole plus trimethoprim (systemic treatment)
Study: 2725163
Drug: Ciprofloxacin (systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (systemic treatment)
Study: 2725163
Drug: Ciprofloxacin plus
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin plus metronidazole (systemic treatment)
Study: 786170
Drug: 0.3% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% tretinoin followed by a potent corticosteroid ointment
Study: 786170
Drug: Corticosteroid ointment
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid ointment alone
Study: 27702846
Drug: Fluoxetine (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10-40 mg daily)
Study: 22669936
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy in the context of palliative care
Study: 22041483
Drug: Timolol eye
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol eye drops administered topically twice per day from the second week through the end of the first month.
Study: 22041483
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no timolol treatment).
Study: 18845976
Drug: Nonvibration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonvibration treatment with passive stretching for five 1-min bouts
Study: 10651782
Drug: Azelastine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 4 mg (oral) once daily for 7 days
Study: 12013487
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg once daily in the morning for 4 weeks
Study: 1538580
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (30 mg/day)
Study: 1980464
Drug: Lormetazepam 1
Normalized name: lormetazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 1 mg
Study: 22804943
Drug: Traditional multimodality
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional multimodality therapy (gastrolavage, catharsis, methylthioninium chloride, vitamin C, symptomatic treatment)
Study: 22804943
Drug: Traditional multimodality
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional multimodality therapy plus scopolamine
Study: 19789153
Drug: Colesevelam hydrochloride,
Normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam hydrochloride, 3.75 g daily
Study: 19789153
Drug: Rosiglitazone maleate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone maleate, 4 mg daily
Study: 19789153
Drug: Sitagliptin phosphate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin phosphate, 100 mg daily
Study: 17983363
Drug: 45 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 degrees raised head of bed (treatment group)
Study: 12946091
Drug: evidence-based consumer
Approvals — FDA: no, EMA: no, PMDA: no
Description: evidence-based consumer guide to treatments for depression
Study: 17305661
Drug: Dexamethasone 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.6 mg/kg
Study: 9197291
Drug: Low-flow sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-flow sevoflurane anesthesia (1 l/min)
Study: 9197291
Drug: High-flow sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-flow sevoflurane anesthesia (6-10 l/min)
Study: 9197291
Drug: Low-flow isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-flow isoflurane anesthesia (1 l/min)
Study: 7951525
Drug: MCI‐028 (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCI‐028 (synthetic human corticotropin-releasing hormone) at doses of 33, 100, and 200 micrograms
Study: 7951525
Drug: MCI‐028 (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCI‐028 (synthetic human corticotropin-releasing hormone)
Study: 3082506
Drug: Monochemotherapy (thiotepa,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochemotherapy (thiotepa, six courses, 200 mg each course)
Study: 24850114
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic with steroids (Group II)
Study: 22414822
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration with 4% articaine with epinephrine
Study: 22414822
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection with 2% lidocaine with epinephrine
Study: 22414822
Drug: Intraligamentary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injection (PDL) with 2% lidocaine with epinephrine
Study: 18377382
Drug: Oral triptans
Normalized name: TripTone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triptans
Study: 18377382
Drug: Effervescent aspirin
Normalized name: aspirin Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent aspirin
Study: 15946914
Drug: Microemulsion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion of cyclosporine, mycophenolatesodium, steroids and basiliximab
Study: 15946914
Drug: Increased cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased cyclosporine (CsA) dose
Study: 15946914
Drug: Decreased CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased CsA dose after 14 days
Study: 6810015
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin preparation given once daily at variable doses
Study: 25913664
Drug: BMS-582949 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-582949 (100 mg once daily)
Study: 21295198
Drug: Warfarin management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin management communication protocol using SBAR approach
Study: 15261316
Drug: MgSO4 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (50 mg kg(‐1) in 100 mL saline, followed by 50 mL hr(‐1) infusion of MgSO4 (15 mg kg(‐1) hr(‐1))
Study: 11389256
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide treatment for PPHN
Study: 11389256
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitric oxide treatment)
Study: 26376350
Drug: Tofacitinib (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (0.5, 3, 10, or 15 mg twice daily)
Study: 23221981
Drug: ALVAC-HIV vCP1521
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV vCP1521 vaccine
Study: 22842667
Drug: PTH (1‐34)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH (1‐34) 20 μg
Study: 22842667
Drug: PTH (1‐84)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH (1‐84) 100 μg
Study: 11986563
Drug: static with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: static with MC plus blur correction plus AC (combined corrections [CC])
Study: 11986563
Drug: gated with
Normalized name: GLUCAGON ANALOG CONJUGATED WITH HUMAN IMMUNOGLOBULIN G4 FRAGMENT
DrugBank: Efocipegtrutide (DB18194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gated with CC
Study: 9653864
Drug: High-dose danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose danazol (600 mg daily)
Study: 9653864
Drug: Low-dose danazol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose danazol (200 mg daily) plus placebo tablets
Study: 7664720
Drug: Biologically fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologically fermented milk product (200 ml/day)
Study: 7664720
Drug: Placebo product
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product (200 ml/day)
Study: 2474017
Drug: L-5-hydroxytryptophan (L5HTP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (L5HTP; 100 mg qid) with carbidopa (C; 50 mg qid)
Study: 26580831
Drug: Topical glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycerol trinitrate (2g once a day for 3 days before laser sessions)
Study: 23229188
Drug: Methotrexate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5 mg/week)
Study: 23229188
Drug: Cyclosporine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (2.5 mg/kg/day)
Study: 16461867
Drug: Primary care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care, office‐based, computer‐assisted diet and PA assessment and stage‐based goal setting followed by brief health care provider counseling and 12 months of monthly mail and telephone counseling
Study: 9287262
Drug: 60 mmol/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mmol/day potassium supplement for four weeks
Study: 9287262
Drug: 48 mmol/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mmol/day potassium supplement for four months
Study: 8346578
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) therapy - intravenous methylprednisolone 2 mg/kg bodyweight daily for ten days
Study: 8346578
Drug: Cotrimoxazole (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (standard treatment)
Study: 3555175
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg three times a day for two weeks
Study: 22927230
Drug: Sufentanil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.4 ng/mL (group SL)
Study: 22927230
Drug: Sufentanil 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.8 ng/mL (group SH)
Study: 21353695
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg subcutaneous every 4 weeks)
Study: 21353695
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenous every 4 weeks)
Study: 19608171
Drug: Supraphysiologic (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiologic (0.2 mg/d transdermal E(2) and vaginal micronized E(2))
Study: 19608171
Drug: Physiologic (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic (0.2 mg/d transdermal E(2))
Study: 19608171
Drug: Subphysiologic (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subphysiologic (no exogenous E(2) treatment)
Study: 15321697
Drug: Quinidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine + Verapamil (high dose) 480/240 mg/d
Study: 15321697
Drug: Quinidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine + Verapamil (low dose) 320/160 mg/d
Study: 15321697
Drug: Sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 320 mg/d
Study: 15321697
Drug: Quinidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine + Verapamil (high dose)
Study: 15321697
Drug: Quinidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine + Verapamil (low dose)
Study: 15321697
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (Quinidine + Verapamil high dose, low dose, Sotalol)
Study: 9671326
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 150 IU/kg three times weekly
Study: 3288951
Drug: Oxybutynin 10
Normalized name: oxyBUTYnin 10% transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 10 mg at suppertime for 28 days
Study: 20411996
Drug: MPA 10
Normalized name: Fycompa 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 10 mg/day
Study: 20411996
Drug: CEE 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.6 mg/day
Study: 16582549
Drug: QUANTEC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUANTEC treatment for 3 months
Study: 16582549
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during first phase)
Study: 11061470
Drug: Budesonide 64
Normalized name: budesonide 64 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 64 microg aqueous nasal spray
Study: 11061470
Drug: Budesonide 256
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 256 microg aqueous nasal spray
Study: 8942009
Drug: salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol 50 micrograms twice daily
Study: 8655889
Drug: salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 200 micrograms twice daily
Study: 1417196
Drug: New polyvalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: New polyvalent melanoma cell vaccine (MCV)
Study: 1417196
Drug: Historical database
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical database of previous immunotherapy and other treatments
Study: 2864709
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg bromazepam per day
Study: 2864709
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg fluspirilene per week
Study: 30266894
Drug: low‐flu/val (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐flu/val (10 mg/20 mg)
Study: 20855047
Drug: Both Sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Sertraline and CBT (COMB)
Study: 20855047
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) without family history of OCD
Study: 14752209
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone replacement therapy
Study: 8135108
Drug: Seaprose S
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaprose S (30 mg tablets, 3 tab/day)
Study: 8135108
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg, 2 tab/day)
Study: 30932776
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (330 mg) and vitamin D3 (0.005 mg or 200 IU) per day
Study: 20197486
Drug: laropiprant 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: laropiprant 40 mg for 10 days + single-dose digoxin 0.5 mg
Study: 20197486
Drug: single-dose digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single-dose digoxin 0.5 mg
Study: 12814902
Drug: Ethanol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.4 g/kg, 22‐28 g) twice daily for 8 days
Study: 8936546
Drug: Caudal bupivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivicaine (0.25%) 2 mg.kg-1 before surgical incision, followed by caudal normal saline infused at the same volume after surgical incision.
Study: 6387197
Drug: Timolol maleate,
Normalized name: Timolol Maleate, Ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol maleate, 20 to 30 mg/day
Study: 27817811
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 18/9.6 μg
Study: 27817811
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI 18 μg
Study: 27817811
Drug: FF MDI
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF MDI 9.6 μg
Study: 26882607
Drug: External use
Normalized name: For External Use Only Label
Approvals — FDA: no, EMA: no, PMDA: no
Description: External use of Shengji Ointment (SO), exchange once every 24 h for 21 days
Study: 22652506
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Study: 22652506
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day meso‐zeaxanthin (MZ), 10 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Study: 22652506
Drug: 17 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 mg/day meso‐zeaxanthin (MZ), 3 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Study: 12232543
Drug: tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tianeptine (37.5 mg)
Study: 12232543
Drug: sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline (50 mg)
Study: 15662091
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/d)